1 / 21

When Engineers meet Bioscientists

When Engineers meet Bioscientists. Gary Wang 10/31/2009. Greener?. IT industry. Biotech. Life Science? Bio-Tech? High-Tech?. May be subjective and will change over time

dobry
Télécharger la présentation

When Engineers meet Bioscientists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. When Engineers meet Bioscientists Gary Wang 10/31/2009

  2. Greener? IT industry Biotech

  3. Life Science? Bio-Tech? High-Tech? • May be subjective and will change over time • No “official” definitions of Life Science, Bio-Tech, and High-Tech but according to North American Industry Classification System (NAICS)

  4. Why? (1) • “80% products of Fry’s Electronics are not necessities of our life.” • -- Judy Wang, Family talk, 2006 • “Daddy, next time when you come to my house, could you bring me a new toy?” • -- Derek Wang, Skype call, 2005

  5. Why? (2) High-tech Impact Biotech Impact

  6. Motivation • 2003 International Technology Roadmap for Semiconductors (ITRS) clearly identifies the integration of electrochemical and electrobiological techniques as one of the system-level design challenges that will be faced beyond 2009 • Electrical engineering technologies and microfluidics can be fully integrated to provide advanced biochemical solutions.

  7. Motivation

  8. What? (1) Learning Technologies Learning Business Lab-on-a-chip technology may soon become an important part of efforts to improve global health particularly through the development of point-of-care testing devices. POCT (Point-of-Care Testing)

  9. IVD (In Vitro Diagnostic) Market

  10. Continuous-Flow Microfluidics • “miniaturized total chemical analysis systems” (µTAS) • the broader terms “microfluidics” and “lab-on-a-chip” are now often used in addition to µTAS.

  11. Digital Microfluidics • electrowetting-on-dielectric (EWOD) • EWOD refers to the modulation of the interfacial tension by applying an electric field • Many advantages of EWOD architecture • We are filing significant IP’s

  12. So? (1) • Very different business model • Very diversified industry with Fragmented markets • Longer development cycle & slower pace • Very different mindset • Not Silicon Valley friendly

  13. Different business model

  14. Technology driven but conservative business ??????????????

  15. Hematology analysis Automated hematology analyzers Coagulation analyzers Blood typing kits Biochemistry analysis Biochemistry systems Dry chemistry systems Blood gas analyzers Electrolyte analysis Lactate meters Glucose meters Immunoassays Competitive immunoassays Sandwich immunoassays Animal-site rapid immunoassays DNA testing Bile acid tests and others Urine test kits Refractometers Blood pressure monitors Pulse oximeters Digital oximeters Capnography Vital signs monitors Anesthesiology equipment Anesthetic machines Breathing systems Ventilators Anesthetic agents Radiography Digital radiography Computed tomography Dental radiography Peripherals and consumables Diagnostic ultrasound Large animal reproduction Small animal reproduction Equine tendon Cardiology Ophthalmology Ultrasound systems Three dimensional ultrasound Magnetic resonance imaging Other imaging Gamma cameras Dermatology imaging PACS Endoscopes Laparoscopes Tract endoscopes Gastroscopes Bronchoscopes Thoracoscopes Cystoscopes Otoscopes Rhinoscopes Veterinary Diagnostic Equipment

  16. Longer development cycle • Reboot is not an option • Regulatory requirements • FDA, The European Medicines Agency (EMEA) and PMDA (Japan)… • Clinical trials • GMP (Good manufacturing practice) • Regional differences/protections • X3 ?

  17. Very different mindset • Know-how? • Anti-big-companies? • Team work? • More individual dependent? • More Self-centered? • Scientistic vs. Engineering? • Degree important?

  18. Not Silicon Valley friendly • Anti-high-tech altitude? • Silicon Valley culture? • Difficult to start from your garage? • Rational decision? • Lack knowledge & appreciation of advanced IT technologies?

  19. So? (2)

  20. Roadkills? • Set the right expectations • Planning is the key • Determination • Reach out • Timing is right • Increasing demands on multi-disciplined talents • No Recession in IVD (2/6/2009 Kalorama Information) • Act now! • Or “120” question

  21. Conclusion

More Related